A detailed history of Janus Henderson Group PLC transactions in Biogen Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 23,029 shares of BIIB stock, worth $3.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,029
Previous 21,129 8.99%
Holding current value
$3.43 Million
Previous $4.9 Million 8.88%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $359,233 - $449,920
1,900 Added 8.99%
23,029 $4.46 Million
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $2.67 Million - $3.32 Million
-14,030 Reduced 39.9%
21,129 $4.9 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $2.97 Million - $3.74 Million
13,985 Added 66.05%
35,159 $7.58 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $19,142 - $23,042
86 Added 0.41%
21,174 $5.48 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $255,073 - $287,891
1,007 Added 5.01%
21,088 $5.42 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $320,666 - $370,539
-1,165 Reduced 5.48%
20,081 $5.72 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $577,516 - $658,057
2,251 Added 11.85%
21,246 $5.91 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $589,194 - $715,884
2,334 Added 14.01%
18,995 $5.26 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $319,486 - $440,542
-1,641 Reduced 8.97%
16,661 $4.45 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $63.9 Million - $76 Million
-340,693 Reduced 94.9%
18,302 $3.73 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $11.2 Million - $14.1 Million
57,550 Added 19.09%
358,995 $75.6 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $36.9 Million - $47.4 Million
164,593 Added 120.27%
301,445 $72.3 Million
Q3 2021

Nov 16, 2021

BUY
$282.99 - $369.05 $13.6 Million - $17.7 Million
47,905 Added 53.86%
136,852 $38.7 Million
Q2 2021

Aug 16, 2021

BUY
$259.0 - $414.71 $3.82 Million - $6.12 Million
14,746 Added 19.87%
88,947 $30.8 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $9.18 Million - $10.8 Million
-37,796 Reduced 33.75%
74,201 $20.8 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $1.87 Million - $2.82 Million
-7,933 Reduced 6.61%
111,997 $27.4 Million
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $1.88 Million - $2.18 Million
-7,117 Reduced 5.6%
119,930 $34 Million
Q2 2020

Aug 14, 2020

BUY
$258.66 - $342.55 $12.3 Million - $16.3 Million
47,633 Added 59.98%
127,047 $34 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $697,128 - $884,316
-2,593 Reduced 3.16%
79,414 $25.1 Million
Q4 2019

Feb 18, 2020

BUY
$220.06 - $304.07 $587,340 - $811,562
2,669 Added 3.36%
82,007 $24.3 Million
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $447,274 - $501,661
-2,057 Reduced 2.53%
79,338 $18.5 Million
Q2 2019

Jul 31, 2019

BUY
$219.29 - $241.72 $719,490 - $793,083
3,281 Added 4.2%
81,395 $19 Million
Q1 2019

Apr 30, 2019

SELL
$216.71 - $338.96 $77.8 Million - $122 Million
-359,200 Reduced 82.14%
78,114 $18.5 Million
Q4 2018

Feb 06, 2019

SELL
$278.5 - $352.75 $21.9 Million - $27.8 Million
-78,806 Reduced 15.27%
437,314 $132 Million
Q3 2018

Nov 09, 2018

SELL
$293.51 - $383.83 $317 Million - $414 Million
-1,079,866 Reduced 67.66%
516,120 $182 Million
Q2 2018

Aug 10, 2018

BUY
$257.52 - $306.91 $7.82 Million - $9.32 Million
30,353 Added 1.94%
1,595,986 $463 Million
Q1 2018

May 14, 2018

BUY
$260.13 - $367.91 $9.69 Million - $13.7 Million
37,247 Added 2.44%
1,565,633 $429 Million
Q4 2017

Feb 09, 2018

BUY
$307.64 - $344.58 $27.1 Million - $30.4 Million
88,235 Added 6.13%
1,528,386 $487 Million
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $1.52 Million - $1.78 Million
-5,409 Reduced 0.37%
1,440,151 $0
Q2 2017

Aug 17, 2017

BUY
N/A
1,445,560
1,445,560 $392 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.